Dramatic Rise in Stem Cell Therapy Use in 2012
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ — RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: “The range and scope of stem cell therapeutic use in the United States grew much faster than we’d forecasted earlier this year. Virtually all of the increases we’re seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth.”
Mr. Young’s revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.
The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8(th) Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.
The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.
The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City’s historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.
Aastrom Biosciences, Inc. Medistem Inc. Advanced Cell Technology Mesoblast Limited Aldagen, Inc. MultiCell Technologies [MCET] AllCells, LLC. Neostem, Inc. Aruna Biomedical, Inc. Neuralstem Athersys, Inc. Opexa Therapeutics, Inc. Bioheart Inc. Osiris Therapeutics, Inc. BioLife Solutions Parcell Labs BioTime Inc./Embryome Sciences, Inc. Pathfinder Cell Therapy Brainstorm Cell Therapeutics Pervasis Therapeutics, Inc. Case Western Reserve University Pluristem Therapeutics, Inc. CellCyte Genetics Corp. Prochon Biotech, Ltd. Celgene Corporation Progenitor Cell Therapy, LLC Celtigen Therapeutics Stem Cell Innovations Cord Blood America, Inc. (CBAI.OB) Stem Cell Therapeutics (SCTPF) Core Dynamics Ltd. StemCells Inc. Cytori Therapeutics, Inc. TiGenix NV Gamida Cell Ltd. Tissue Genesis, Inc. Garnet BioTherapeutics, Inc. TxCell Histogen Inc Vet-Stem, Inc. INCELL Corporation LLC ViaCyte International Stem Cell Corporation WuXi AppTec Lifenet Health Lonza Group Ltd.
In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.
8th Annual New York Stem Cell Summit Facts at a Glance What: Largest Gathering of Stem Cell Company Executives, Scientists, Investors, and Physicians When: February 19, 2013 Where: Bridgewaters 11 Fulton Street New York City Who: The Stem Cell Summit is organized by RRY Publications LLC Admission: $950 through November 2012 $1,500 Registration (February 1, 2013 - February 19, 2013 and onsite) Information: For more information on presentation or sponsorship opportunities, call Bharathi Kavalipati at 610-260-6462 or send an email to firstname.lastname@example.org Additional information, including attendee registration details, is available at www.stemcellsummit.com
Contacts: Suzanne Kirchner RRY Publications LLC 501-251-1797 email@example.com
SOURCE RRY Publications LLC